HQL-79

HQL-79 is a selective inhibitor of hematopoietic prostaglandin D (PGD) synthase. Structurally, it is a synthetic tetrazole compound originally prepared as a possible antihistamine.¹ Subsequent evaluation in models of allergy and asthma demonstrates the HQL-79 is orally available, and inhibits the synthesis of PGD₂ (Item No. 12010).² HQL-79 is thus a likely lead compound for the preparation of potent, selective hematopoietic PGD synthase inhibitors.

WARNING This product is not for human or veterinary use.

1. Matsushita, K., Nobutoshi, A., and Aritake, K. Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antiasthmatic effects. Jpn. J. Pharmacol. 78(1), 11-22 (1998).

2. Matsushita, K., Nobutoshi, A., and Hizue, A. Pharmacological studies on the novel antiallergic drug HQL-79: I. Antiallergic and antiasthmatic effects in various experimental models. Jpn. J. Pharmacol. 78(1), 1-10 (1998).

Schröder, R., Xue, L., Konya, V., et al. PGH₁, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP₂. PLoS One 7(3), e33329 (2012).

Farhat, A., Philibert, P., Sultan, C., et al. Hematopoietic-Prostaglandin D₂ synthase through PGD₂ production is involved in the adult ovarian physiology. J. Ovarian Res. 4, 3 (2011).